Eurocor Gmbh an Opto Circuits company has received CE mark approval of its new polymer-free, TAXCOR I.Paclitaxel-eluting coronary stent system. Though polymer-free, this innovative
drug-eluting stent technology eliminates any polymer-related, late adverse effect
potential for the patient, like subacute thrombosis.
My
Iris
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Paige Earns CE Mark for Prostate Cancer Detection Solution
“Pathology practices around the world have begun to embrace digital pathology,” said Paige CEO Leo Grady.
Ranitidine Tests Find NDMA Levels Akin to Levels in Food, Woodcock Says
The agency asked manufacturers to voluntarily recall another H2 blocker nizatidine, or Axid, if they find NDMA above the acceptable daily intake level.
FDAnews Device Daily Bulletin
EUROCOR GMBH RECEIVES CE MARK APPROVAL FOR TAXCOR I
July 11, 2006
